Search research articles
Contact Us
Filters
Showing results (61-70 of 93) with videos related to
Page
of 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Keith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 27, 2016
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL
Roni Engelstein, Sharon Merims, Galit Eisenberg, et al.
Frontiers in Immunology
|
May 29, 2026
Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics
Bohdana Chayen, Gal Dinstag, Omer Tirosh, et al.
Journal of Neuro-Oncology
|
January 15, 2018
Neurologic complications of immune checkpoint inhibitors
Avi Fellner, Chen Makranz, Michal Lotem, et al.
Anticancer Research
|
July 26, 2024
The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
Ofra Maimon, Benjamin Nisman, Shani Broier, et al.
Clinical Chemistry and Laboratory Medicine
|
May 17, 2018
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
Panagiota S Filippou, Annie H Ren, Dimitrios Korbakis, et al.
Journal of Hepatology
|
December 22, 2024
RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions
Einat Cinnamon, Ilan Stein, Elvira Zino, et al.
JAAD International
|
November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemics
Deborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Elife
|
March 4, 2020
SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
Emma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Journal of the American Academy of Dermatology
|
December 22, 2018
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
Lise Boussemart, Adrienne Johnson, Alexa B Schrock, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 93) with videos related to
Sort By:
Page
of 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2025
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Keith T Flaherty, Andrew E Aplin, Michael A Davies, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 27, 2016
Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL
Roni Engelstein, Sharon Merims, Galit Eisenberg, et al.
Frontiers in Immunology
|
May 29, 2026
Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomics
Bohdana Chayen, Gal Dinstag, Omer Tirosh, et al.
Journal of Neuro-Oncology
|
January 15, 2018
Neurologic complications of immune checkpoint inhibitors
Avi Fellner, Chen Makranz, Michal Lotem, et al.
Anticancer Research
|
July 26, 2024
The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
Ofra Maimon, Benjamin Nisman, Shani Broier, et al.
Clinical Chemistry and Laboratory Medicine
|
May 17, 2018
Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases
Panagiota S Filippou, Annie H Ren, Dimitrios Korbakis, et al.
Journal of Hepatology
|
December 22, 2024
RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions
Einat Cinnamon, Ilan Stein, Elvira Zino, et al.
JAAD International
|
November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemics
Deborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Elife
|
March 4, 2020
SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
Emma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Journal of the American Academy of Dermatology
|
December 22, 2018
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma
Lise Boussemart, Adrienne Johnson, Alexa B Schrock, et al.
Page
of 10